Similar Items: Pharmacokinetics, pharmacogenetics and optimisation of treatment with non-nucleoside reverse transcriptase inhibitors in HIV-infected African children
- Pharmacometrics of dolutegravir and tenofovir: a quantitative approach to characterise drug-drug interactions, pharmacogenetics and optimise treatment
- Lead optimisation of an indole based HIV-1 non-nucleoside reverse transcriptase inhibitor
- Indole- and diaryl ether-derived non-nucleoside reverse transcriptase inhibitors
- Efavirenz pharmacogenetics and metabolic toxicity in black South Africans
- Population pharmacokinetic and pharmacodynamic modelling to improve tuberculosis treatment
- The rational design and synthesis of novel HIV non-nucleoside reverse transcriptase inhibitors
Author: Denti, Paolo
- Pharmacometric modelling to inform and improve TB and HIV treatment: Focus on drug-drug interactions and neglected populations
- Pharmacokinetics, pharmacogenetics and optimisation of treatment with non-nucleoside reverse transcriptase inhibitors in HIV-infected African children
- Population pharmacokinetic modelling to optimise treatment for children with Rifampicin-resistant TB and HIV
- Population pharmacokinetic and pharmacodynamic modelling to improve tuberculosis treatment
- A scoping review on the use of telerehabilitation in physiotherapy in low and middle income countries
- Advancing tuberculosis treatment through pharmacometric modeling of drug exposure and biomarkers